Chinese pharma company BeiGene has agreed to pay Ambrx $10 million upfront to experiment with technology the biotech has developed in a bid accelerate BeiGene’s search for new protein drugs for cancer treatment.
Ambrx says its technology is able to incorporate... Read more »
Much has been said about Lyft’s early lead over Uber in the “horserace” to become the first ride-hailing app company to go public. But now that San Francisco-based Lyft has filed its 276-page IPO prospectus with the U.S. Securities and Exchange... Read more »
About three months ago, Apple announced it planned to add 1,000 jobs in the San Diego region over the next three years. On Wednesday, the Cupertino, CA-based tech giant said it would increase that total by 200 jobs as part of... Read more »
Erasca, a biotech startup run by the former CEO of Ignyta, debuted in December with $42 million and an audacious plan to “erase cancer,” but provided little explanation as to how.
Erasca is still keeping many of those details under wraps.... Read more »
Austin—All politics is local, the adage goes, and those campaigns are sorely stuck in analog mode.
That’s why Shion Deysarkar co-founded Blue Squad two years ago as a “digital coalition” to support progressive candidates by providing them with greater access... Read more »
Two months after insisting on Twitter that he wasn’t going anywhere, Food and Drug Administration Commissioner Scott Gottlieb announced his resignation today. He leaves a record of health and medical regulation that was more active than critics who spoke out... Read more »
One size fits most (at best), and a women’s sizing system created during the Depression doesn’t gibe in an e-commerce business that prizes personalization.
That’s why startups are turning to new technologies like 3D scanning and machine learning software to produce... Read more »
Privacy issues continued to boil to the surface in February. In part, it’s a reflection of the long tail of consequences that began in early 2018 when the broader public learned that Facebook had shared data from millions of user profiles... Read more »
After years of boom times, the U.S. biopharmaceutical industry is dealing with unprecedented threats on several fronts: public backlash against high drug prices, slowing sales, and the possibility of more government regulation.
In this Xconomy Special Report, our veteran biotech journalists... Read more »